Go Pro
→ SpaceX pays a 10X launch penalty (From Freedom Financial) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CalciMedica Inc. stock logo
CALC
CalciMedica
$2.02
-6.9%		$3.54
$1.99
▼
$36.00
$14.82M0.8387,983 shs122,568 shs
Neuralstem, Inc. stock logo
CUR
Neuralstem
$1.87
-2.1%		$1.06
$1.10
▼
$13.78
$3.93M1.81236,278 shs1.84 million shs
Scienture Holdings, Inc. stock logo
SCNX
Scienture
$0.36
-2.5%		$0.39
$0.24
▼
$2.60
$15.32M3.253.48 million shs210,964 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$3.11
-13.5%		$4.29
$1.11
▼
$17.50
$13.12M0.162,997 shs821 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CalciMedica Inc. stock logo
CALC
CalciMedica
0.00%+1.40%-36.87%-52.31%-85.91%
Neuralstem, Inc. stock logo
CUR
Neuralstem
0.00%0.00%0.00%0.00%+198.48%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
0.00%-3.99%-1.87%+1.91%-57.91%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00%-15.69%-10.45%+6.60%-75.76%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CalciMedica Inc. stock logo
CALC
CalciMedica
$2.02
-6.9%		$3.54
$1.99
▼
$36.00
$14.82M0.8387,983 shs122,568 shs
Neuralstem, Inc. stock logo
CUR
Neuralstem
$1.87
-2.1%		$1.06
$1.10
▼
$13.78
$3.93M1.81236,278 shs1.84 million shs
Scienture Holdings, Inc. stock logo
SCNX
Scienture
$0.36
-2.5%		$0.39
$0.24
▼
$2.60
$15.32M3.253.48 million shs210,964 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$3.11
-13.5%		$4.29
$1.11
▼
$17.50
$13.12M0.162,997 shs821 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CalciMedica Inc. stock logo
CALC
CalciMedica
0.00%+1.40%-36.87%-52.31%-85.91%
Neuralstem, Inc. stock logo
CUR
Neuralstem
0.00%0.00%0.00%0.00%+198.48%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
0.00%-3.99%-1.87%+1.91%-57.91%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00%-15.69%-10.45%+6.60%-75.76%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CalciMedica Inc. stock logo
CALC
CalciMedica
2.20
Hold$50.002,375.25% Upside
Neuralstem, Inc. stock logo
CUR
Neuralstem
0.00
N/AN/AN/A
Scienture Holdings, Inc. stock logo
SCNX
Scienture
2.00
Hold$1.50312.43% Upside
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CUR, SCNX, ZIVO, and CALC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
CalciMedica Inc. stock logo
CALC
CalciMedica
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/20/2026
CalciMedica Inc. stock logo
CALC
CalciMedica
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
8/13/2026
CalciMedica Inc. stock logo
CALC
CalciMedica
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/13/2026
CalciMedica Inc. stock logo
CALC
CalciMedica
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
7/29/2026
CalciMedica Inc. stock logo
CALC
CalciMedica
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/29/2026
CalciMedica Inc. stock logo
CALC
CalciMedica
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
7/7/2026
CalciMedica Inc. stock logo
CALC
CalciMedica
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
Scienture Holdings, Inc. stock logo
SCNX
Scienture
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CalciMedica Inc. stock logo
CALC
CalciMedica
N/AN/AN/AN/A($2.30) per shareN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
$260K15.10N/AN/A$6.64 per share0.28
Scienture Holdings, Inc. stock logo
SCNX
Scienture
$430K34.73N/AN/A$1.73 per share0.21
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$15.85K827.68N/AN/A($0.81) per share-3.84
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CalciMedica Inc. stock logo
CALC
CalciMedica
-$29.56M-$6.80N/AN/AN/AN/A-863.40%-155.24%11/11/2026 (Estimated)
Neuralstem, Inc. stock logo
CUR
Neuralstem
-$4.93MN/AN/AN/AN/A-39,417.64%-170.51%-110.16%N/A
Scienture Holdings, Inc. stock logo
SCNX
Scienture
-$41.51M-$2.10N/AN/AN/AN/A-53.51%-42.47%11/12/2026 (Estimated)
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
-$7.78M-$1.40N/AN/AN/AN/AN/A-2,240.92%N/A

Latest CUR, SCNX, ZIVO, and CALC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Scienture Holdings, Inc. stock logo
SCNX
Scienture
-$0.09-$0.07+$0.02-$0.07$1.96 million$0.34 million
8/11/2026Q2 2026
CalciMedica Inc. stock logo
CALC
CalciMedica
-$1.4250-$0.45+$0.9750-$2.25N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CalciMedica Inc. stock logo
CALC
CalciMedica
N/AN/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/AN/AN/AN/AN/A
Scienture Holdings, Inc. stock logo
SCNX
Scienture
N/AN/AN/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CalciMedica Inc. stock logo
CALC
CalciMedica
1.67
5.58
5.58
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/A
2.53
2.53
Scienture Holdings, Inc. stock logo
SCNX
Scienture
0.15
3.04
2.97
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/A
0.17
0.17

Institutional Ownership

CompanyInstitutional Ownership
CalciMedica Inc. stock logo
CALC
CalciMedica
N/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
38.30%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
5.68%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
12.83%

Insider Ownership

CompanyInsider Ownership
CalciMedica Inc. stock logo
CALC
CalciMedica
28.25%
Neuralstem, Inc. stock logo
CUR
Neuralstem
5.38%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
21.39%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
48.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
CalciMedica Inc. stock logo
CALC
CalciMedica
306.83 million4.90 millionNo Data
Neuralstem, Inc. stock logo
CUR
Neuralstem
62.10 millionN/ANot Optionable
Scienture Holdings, Inc. stock logo
SCNX
Scienture
N/A41.06 million32.28 millionN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
104.22 million2.91 millionNot Optionable

Recent News About These Companies

Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512411739/en/zivo-bioscience-inc.-announces-transition-to-otcid-marketplace/
Zivo Bioscience Inc. Wt
April 11, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/zivow
ZIVO Bioscience Provides Special Letter to Shareholders
March 27, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260327190358/en/ZIVO-Bioscience-Provides-Special-Letter-to-Shareholders/
Maxim Group Reaffirms Their Hold Rating on Zivo Bioscience (ZIVO)
December 15, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ZIVO/pressreleases/36474537/maxim-group-reaffirms-their-hold-rating-on-zivo-bioscience-zivo/
ZIVO Bioscience releases letter to shareholders
September 14, 2025  |  wattagnet.comW
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
September 10, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250910182550/en/zivo-bioscience-ceo-letter-to-shareholders-highlights-progress-with-human-nutrition-and-animal-therapeutic-businesses/
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry
June 20, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250620564330/en/zivo-bioscience-and-leading-global-animal-health-company-to-advance-zivo%e2%80%99s-immune-enhancing-compounds-in-poultry/
University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 7, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/university-delaware-study-identifies-optimal-215400486.html
University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250506414477/en/university-of-delaware-study-identifies-optimal-formulation-of-zivo%e2%80%99s-active-ingredients-for-further-testing-to-mitigate-avian-influenza-in-poultry/
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
February 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250206639313/en/zivo-bioscience-plans-new-study-with-university-of-delaware-to-combat-avian-influenza-in-poultry/
Zivo Bioscience issues new shares, raises $1.5 million
January 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/zivo-bioscience-issues-new-shares-raises-1-5-million/ar-AA1xZjTM
Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed
January 1, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/tuesdays-insider-activity-top-buys-and-sells-in-us-stocks-revealed-93CH-3793355
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
December 20, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20241220941955/en/ZIVO-Bioscience-Reports-Preliminary-Efficacy-of-its-Proprietary-Active-Ingredients-in-the-Battle-Against-Avian-Influenza/
ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023
March 18, 2024  |  investorplace.comhttps://investorplace.com/earning-results/2024/03/zivo-stock-earnings-zivo-bioscience-for-q4-of-2023/?utm_source=marketbeat&utm_medium=referral
Regencell Bioscience Holdings Ltd RGC
February 1, 2024  |  morningstar.comM
ZIVO Bioscience Announces Uplisting to OTCQB Market
January 29, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/zivo-bioscience-announces-uplisting-otcqb-130000877.html?.tsrc=rss
Ideaya Biosciences
January 18, 2024  |  forbes.comhttps://www.forbes.com/companies/ideaya-biosciences/
Dare Bioscience Inc DARE
January 14, 2024  |  morningstar.comM
Zivo Bioscience Inc (ZIVO) USD0.001
November 11, 2023  |  hl.co.ukhttps://www.hl.co.uk/shares/shares-search-results/z/zivo-bioscience-inc-usd1.001/costs
Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72
November 1, 2023  |  msn.comhttps://www.msn.com/en-us/money/markets/zivo-bioscience-zivo-price-target-increased-by-50000-to-3672/ar-AA1jflXo

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
The Metals Company logo displayed over an image of polymetallic nodules on the seafloor with sea stars.
The Metals Company’s Big Bet Now Comes Down to a License
By Thomas Hughes | August 16, 2026
Illustration of a computer chip on a circuit board with an upward green stock chart line in a server room.
Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
By Thomas Hughes | August 31, 2026
Server racks in a data center aisle with an overlaid digital network graphic and cloud icons above.
3 of the Market's Most-Upgraded Tech Stocks Right Now
By Ryan Hasson | August 10, 2026
Illuminated glass panel displaying the Okta logo in a dark server room and office setting.
Okta’s AI Tailwind Could Put This Forgotten Software Stock Back in Play
By Sam Quirke | August 19, 2026
Illustration of a glowing digital shield and lock blocking red virus icons in a server data center.
3 Ways to Invest in Cybersecurity Through ETFs
By Dan Schmidt | August 20, 2026
CalciMedica stock logo

CalciMedica NASDAQ:CALC

$2.02 -0.15 (-6.91%)
Closing price 04:00 PM Eastern
Extended Trading
$2.09 +0.07 (+3.51%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Neuralstem stock logo

Neuralstem NASDAQ:CUR

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Scienture stock logo

Scienture NASDAQ:SCNX

$0.36 -0.01 (-2.49%)
Closing price 04:00 PM Eastern
Extended Trading
$0.36 0.00 (-0.19%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

ZIVO Bioscience stock logo

ZIVO Bioscience NASDAQ:ZIVO

$3.11 -0.49 (-13.54%)
As of 02:36 PM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas